Recent Advances in the Treatment and Management of Heart Failure: Expert Perspectives on the Role of New and Emerging Therapies

A continuing medical education activity provided by NAMCP and AAMCN

This activity is an archive from the live session from the 2021 Fall Managed Care Forum.
If you participated in the live session, you are not eligible for continuing
education credits from this archive.

This activity is valid from January 1, 2022, to March 1, 2023.

Instructions for CME/NCPD: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.


Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This activity is supported by an educational grant from
Merck Sharp & Dohme Corp.

Heart failure (HF) is a common condition that affects approximately 5.7 million people in the United States, and the prognosis for patients with heart failure has traditionally been poor. HF is the reason for more than 1 million hospitalizations per year and an estimated $31 billion in costs in the U.S. each year. While recent efforts have focused on improving the outlook for patients with chronic heart failure, mortality and morbidity following admission for heart failure remain significant. In recent decades, an improved understanding of the pathobiology of HF has led to the introduction of a number of new classes of medications that have improved the clinical outcomes of HF patients. However, despite these advances, nearly 6 million people in the United States have HF. The 5-year mortality rate for HF remains unacceptably high at about 50%, and 30-day HF patient readmissions are approximately 25%. Although multiple therapies have been shown to lower mortality in patients with HF, their applications in clinical practice have been less than ideal. Fortunately for patients with HF, new and emerging therapeutic options have entered the treatment paradigm recently, including SGLT2 inhibitors, showing the ability to reduce the risk of cardiovascular (CV) death or the worsening of heart failure in patients with heart failure both with and without type 2 diabetes.

Upon completion of this activity, participants will be able to:

  • Quantify the clinical and economic burden of heart failure (HF), including factors that contribute to HF-related hospitalizations and increased costs

  • Compare and contrast efficacy and safety profiles and recent clinical data of new and emerging therapies in HF, including patients with high-risk HF with reduced ejection fraction (HFrEF)

  • Identify patients at high risk for worsening heart failure to prevent life-threatening events through prompt intervention

  • Align treatment decision-making with new evidence on treatment selection based on individual patient-specific factors

  • Implement best practices that bridge gaps in healthcare disparities to ensure evidence-based, equitable access to new and emerging treatment for heart failure to improve long-term patient outcomes


Faculty: Michael Miller, MD, FACC, FAHA, FASPC, FNLA
Professor of Cardiovascular Medicine, Epidemiology & Public Health
University of Maryland School of Medicine


Michael Miller, MD has no financial relationships with ineligible companies to disclose.
Planning Committee: Bill Williams, MD has no financial relationships with ineligible companies to disclose.
Jeremy Williams has no financial relationships with ineligible companies to disclose.
Jacqueline Cole, RN, MS, CMCN has no financial relationships with ineligible companies to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the National Association of Managed Care Physicians (NAMCP) and American Association of Managed Care Nurses (AAMCN). The National Association of Managed Care Physicians is accredited by the ACCME to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category 1 credit(s)TM. Each
physician should claim credit commensurate with the extent of their participation in the activity.

The American Association of Managed Care Nurses is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

Nurses who complete this activity and achieve a passing score will receive 1 hour in nursing continuing professional development.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hours toward CMCN recertification requirements.

This activity is supported by an educational grant from
Merck Sharp & Dohme Corp.

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue